Business Context and Reporting Period
Company: Keros Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 25, 2021
Reporting Period: Single event date (March 25, 2021)
Business Context: The Company is an emerging growth company incorporated in Delaware, trading on The Nasdaq Stock Market LLC under the symbol "KROS". This filing serves as a Regulation FD disclosure regarding an update to the Company's corporate presentation.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a corporate presentation update and does not contain audited or unaudited financial statements.
Material Changes
Corporate Presentation Update: On March 25, 2021, Keros Therapeutics updated its corporate presentation for use in meetings with investors and analysts. A copy of this presentation is attached as Exhibit 99.1.
Guidance, Outlook, and Risks
Management Commentary: The filing states that the information contained herein, including the attached corporate presentation, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. Consequently, the information is not subject to the liabilities of that section and is not incorporated by reference into other filings unless expressly set forth by specific reference.
Risks and Contingencies: No specific risks or contingencies are detailed within the text of this 8-K filing.
Investor Verification Checklist
- Review Exhibit 99.1 (Corporate Presentation dated March 2021) for specific operational updates, pipeline data, or financial projections not included in this summary.
- Verify the Company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.
- Confirm that the information in the attached presentation is not automatically incorporated by reference into other SEC filings.